Nearly 20 years since the first antibody-drug conjugate was launched, there are still only six on the market. Recent scientific advances have improved the outlook, though, and R&D is picking up pace.
Bringing an antibody-drug conjugate (ADC – an antibody linked to a therapeutic payload) to approval offers the opportunity to participate...






